doi.org
Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
August 2024 • Tufia C. Haddad, Vera J. Suman, Karthik V. Giridhar, Kostandinos Sideras, Donald W. Northfelt, Brenda Ernst, Ciara C. O’Sullivan, Ravinder J. Singh, …
<p>Supplemental Table 2: All adverse events among those patients who discontinued ANA1 early or did not continue onto ANA10 after IES finding due to toxicity.</p>